Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by RalphRalphon Nov 08, 2020 5:39pm

156 Views

Post# 31859955

RE:RE:RE:RE:RE:RE:RE:Opinion

Did you check my post history before leveling that accusation? Or did you just simplistically assume that a critical perspective must correlate to a short position?

Do you have confidence in Antibe's management? If so, what gives you confidence in them?

Arbourmark wrote:
Ralph,

As per my last reply, why would you invest in ATE if they have sub par management?

I believe management has acknowledged that dental acquisition did not pan out.

My point is everyone on this board knows about this failure. So what is the point on continuously posting this negative chapter, unless your motivation is to see share price to go lower. Possibly you own a short position, possibly you hope the price goes lower so you can add to your position.